42 USC 285a-13 - Scientific framework for recalcitrant cancers

U.S Code last checked for updates: Nov 22, 2024

§ 285a–13.

Scientific framework for recalcitrant cancers

(a)

Development of scientific framework

(1)

In general

(2)

Contents

The scientific framework with respect to a recalcitrant cancer shall include the following:

(A)

Current status

(i)

Review of literature

A summary of findings from the current literature in the areas of—

(I)

the prevention, diagnosis, and treatment of such cancer;

(II)

the fundamental biologic processes that regulate such cancer (including similarities and differences of such processes from the biological processes that regulate other cancers); and

(III)

the epidemiology of such cancer.

(ii)

Scientific advances

(iii)

Researchers

(iv)

Coordinated research initiatives

(v)

Research resources

(B)

Identification of research questions

(C)

Recommendations

Recommendations for appropriate actions that should be taken to advance research in the areas described in subparagraph (A)(i) and to address the research questions identified in subparagraph (B), as well as for appropriate benchmarks to measure progress on achieving such actions, including the following:

(i)

Researchers

(ii)

(iii)

Research resources

(3)

Timing

(A)

Initial development and subsequent update

For each recalcitrant cancer identified under subsection (b)(1), the Director of the Institute shall—

(i)

develop a scientific framework under this subsection not later than 18 months after January 2, 2013; and

(ii)

review and update the scientific framework not later than 5 years after its initial development.

(B)

Other updates

(4)

Public notice

With respect to each scientific framework developed under subsection (a), not later than 30 days after the date of completion of the framework, the Director of the Institute shall—

(A)

submit such framework to the Committee on Energy and Commerce and Committee on Appropriations of the House of Representatives, and the Committee on Health, Education, Labor, and Pensions and Committee on Appropriations of the Senate; and

(B)

make such framework publically available on the Internet website of the Department of Health and Human Services.

(b)

Identification of recalcitrant cancer

(1)

In general

Not later than 6 months after January 2, 2013, the Director of the Institute shall identify two or more recalcitrant cancers that each—

(A)

have a 5-year relative survival rate of less than 20 percent; and

(B)

are estimated to cause the death of at least 30,000 individuals in the United States per year.

(2)

Additional cancers

(c)

Working groups

(d)

Reporting

(1)

Biennial reports

The Director of NIH shall ensure that each biennial report under section 283 of this title includes information on actions undertaken to carry out each scientific framework developed under subsection (a) with respect to a recalcitrant cancer, including the following:

(A)

Information on research grants awarded by the National Institutes of Health for research relating to such cancer.

(B)

An assessment of the progress made in improving outcomes (including relative survival rates) for individuals diagnosed with such cancer.

(C)

An update on activities pertaining to such cancer under the authority of section 285a–2(b)(7) of this title.

(2)

Additional one-time report for certain frameworks

(e)

Recommendations for exception funding

(f)

Definition

(July 1, 1944, ch. 373, title IV, § 417G, as added Pub. L. 112–239, div. A, title X, § 1083, Jan. 2, 2013, 126 Stat. 1960.)

cite as: 42 USC 285a-13